Newbury Pharmaceuticals Q1: Initial Take - Redeye

Redeye leaves an initial comment following the Q1 report published by Newbury this morning. Although we anticipated relatively conservative figures for the period, we are encouraged to see that net sales were much higher than our estimates. The increased amount of products on the market and recent partnership deals are now beginning to be reflected in sales growth. Overall, while the EBIT was slightly below our expectations, we are encouraged by the company's Q1 figures.

Länk till analysen i sin helhet: https://www.redeye.se/research/969858/newbury-pharmaceuticals-q1-initial-take-2?utm_source=finwire&utm_medium=RSS